Anocca dosed first patients with KRAS-targeted TCR-T therapy
ANOC-001 is a non-viral gene-edited therapy for pancreatic ductal adenocarcinoma, part of the VIDAR-1 clinical programme.
See the latest news and media coverage for Anocca. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing precision T-cell immunotherapies
anocca.comLast updated
In short: Anocca dosed the first patients in a clinical trial for its pancreatic cancer TCR-T cell therapy after securing $46 million in funding.
ANOC-001 is a non-viral gene-edited therapy for pancreatic ductal adenocarcinoma, part of the VIDAR-1 clinical programme.
The minutes contain decisions from the annual general meeting and can be downloaded as a PDF.
The meeting is held in Stockholm with proposals for emissions and election of board.
The report is available as a PDF and summarizes the company's financial results.
Anocca AB (‘Anocca’ or the ‘Company’), a clinical-stage biotechnology company developing advanced T-cell immunotherapies, ...
Swedish biotechnology company Anocca has secured approximately Skr440m ($46m) to primarily support...
MaxCyte's Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca's TCR-T cell therapies ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) ...
• First in human-study VIDAR-1 in advanced pancreatic cancer will be conducted at eight leading university hospitals in Sweden, Denmark, Germany and the Netherlands • Anocca is a Swedish...
Track Anocca and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Anocca and other trending companies.